Skip to main content
Przejdź do strony domowej Komisji Europejskiej (odnośnik otworzy się w nowym oknie)
polski pl
CORDIS - Wyniki badań wspieranych przez UE
CORDIS

Unlocking Immunotherapy Potential with CapCure: A Novel Chemical Antagonist of PSME4

Cel

Immunotherapy has transformed cancer treatment, yet many patients fail to benefit because their tumors develop intrinsic mechanisms to block immune attack. Recent discoveries from our ERC-funded work revealed that the proteasome, a central protein degradation system, can be hijacked by tumors to suppress immune recognition and promote an immunosuppressive environment.

This Proof of Concept project aims to translate these findings into a novel therapeutic approach. We will develop and validate small molecules that block this tumor-associated mechanism, restoring the ability of the immune system to detect and eliminate cancer cells. Our focus will be on two major cancers with a high unmet need, non–small cell lung cancer and aggressive breast cancer, where resistance to immunotherapy remains a critical challenge.

The project will combine the development of a small molecule which will allow us to modulate proteasomes activity, together with preclinical validation, and a commercialization pathway including intellectual property protection and market analysis. By the end of the project, we expect to deliver optimized drug candidates and a biomarker-guided framework to identify patients most likely to benefit.

Ultimately, this work seeks to establish a new therapeutic class that enhances the effectiveness of existing immunotherapies, with the long-term goal of improving outcomes for patients whose cancers currently remain resistant to treatment.

Dziedzina nauki (EuroSciVoc)

Program(-y)

Temat(-y)

System finansowania

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

Wyświetl wszystkie projekty finansowane w ramach tego programu finansowania

Zaproszenie do składania wniosków

(odnośnik otworzy się w nowym oknie) ERC-2026-POC

Wyświetl wszystkie projekty finansowane w ramach tego zaproszenia

Instytucja przyjmująca

WEIZMANN INSTITUTE OF SCIENCE
Wkład UE netto
€ 150 000,00
Koszt całkowity
Brak danych

Beneficjenci (1)